News Release

Flu vaccines and cancer immunotherapy in mice

Peer-Reviewed Publication

Proceedings of the National Academy of Sciences

Researchers report that flu vaccine injections into tumors in mice can reduce tumor growth and sensitize tumors to immunotherapy. Cancer immunotherapy, which uses the body's immune system to destroy tumor cells, is particularly effective in tumors in an immune-infiltrated "hot" state. Only a minority of tumors are hot, however, limiting the number of people who can benefit from immunotherapies. Andrew Zloza and colleagues injected seasonal flu vaccine without synthetic adjuvants, which are compounds that enhance immune response, directly into tumors in mice. Monitoring indicators of tumor immune sensitivity, the authors found that cold tumors injected with the vaccine experienced systemic immune responses and sensitivity to treatments that block tumors' anti-immune defenses. The results suggest that the tumors had become hot, and that the injection had the additional benefit of conferring protection against influenza. Similar injection of flu vaccine with a synthetic adjuvant resulted in a different response, in which mice were protected from influenza, but the tumors' anti-immune defenses remained in place. Removal of the adjuvant or depletion of immune-suppressive tumor B cells restored the vaccine's proimmune effect on tumors. According to the authors, antipathogen vaccines may find additional benefit as cancer immunotherapies.

Article #19-04022: "Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer," by Jenna H. Newman et al.

MEDIA CONTACT: Andrew Zloza, Rush University Medical Center, Chicago, IL; e-mail:


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.